174 related articles for article (PubMed ID: 37536222)
1. A meta analysis on the utility of Anakinra in severe COVID-19 disease.
Mohamed Hussein AAR; Sayad R; Abdelshafi A; Hammam IA; Kedwany AM; Elkholy SA; Ibrahim IH
Cytokine; 2023 Sep; 169():156311. PubMed ID: 37536222
[TBL] [Abstract][Full Text] [Related]
2. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
6. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
7. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.
Pasin L; Cavalli G; Navalesi P; Sella N; Landoni G; Yavorovskiy AG; Likhvantsev VV; Zangrillo A; Dagna L; Monti G
Eur J Intern Med; 2021 Apr; 86():34-40. PubMed ID: 33581979
[TBL] [Abstract][Full Text] [Related]
8. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
[TBL] [Abstract][Full Text] [Related]
10. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.
Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O
Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576
[TBL] [Abstract][Full Text] [Related]
11. Current evidence on the use of anakinra in COVID-19.
Khani E; Shahrabi M; Rezaei H; Pourkarim F; Afsharirad H; Solduzian M
Int Immunopharmacol; 2022 Oct; 111():109075. PubMed ID: 35905562
[TBL] [Abstract][Full Text] [Related]
12. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).
Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A
J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817
[TBL] [Abstract][Full Text] [Related]
13. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis.
Barkas F; Filippas-Ntekouan S; Kosmidou M; Liberopoulos E; Liontos A; Milionis H
Rheumatology (Oxford); 2021 Dec; 60(12):5527-5537. PubMed ID: 33999135
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis.
Malık H; Bınt Abdul Jabbar H; Latıf F; Sarfraz A; Sarfraz Z; Sarfraz M
Turk J Med Sci; 2022 Jun; 52(3):547-553. PubMed ID: 36326309
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
16. Systemic corticosteroids for the treatment of COVID-19.
Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
[TBL] [Abstract][Full Text] [Related]
17. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.
Udomsinprasert W; Jittikoon J; Sangroongruangsri S; Chaikledkaew U
J Clin Immunol; 2021 Jan; 41(1):11-22. PubMed ID: 33128665
[TBL] [Abstract][Full Text] [Related]
18. An open label trial of anakinra to prevent respiratory failure in COVID-19.
Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
Elife; 2021 Mar; 10():. PubMed ID: 33682678
[TBL] [Abstract][Full Text] [Related]
19. Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
Shang W; Zhang Y; Wang G; Han D
Rev Med Virol; 2023 Mar; 33(2):e2418. PubMed ID: 36600551
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.
Kharazmi AB; Moradi O; Haghighi M; Kouchek M; Manafi-Rasi A; Raoufi M; Shoaei SD; Hadavand F; Nabavi M; Miri MM; Salarian S; Shojaei S; Khalili S; Sistanizad M; Sadeghi S; Karagah A; Asgari S; Jaffaraghaei M; Araghi S
Immun Inflamm Dis; 2022 Feb; 10(2):201-208. PubMed ID: 34762351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
